IRONWOOD PHARMACEUTICALS, INC. Payments of Debt Issuance Costs
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Payments of Debt Issuance Costs of $2.25 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-02-26
- IRONWOOD PHARMACEUTICALS, INC. payments of debt issuance costs for the quarter ending 2024-12-31 was $90.00K, a 84.77% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. payments of debt issuance costs for the quarter ending 2023-12-31 was $591.00K.
- IRONWOOD PHARMACEUTICALS, INC. payments of debt issuance costs for the quarter ending 2023-09-30 was $0.00.
- IRONWOOD PHARMACEUTICALS, INC. payments of debt issuance costs for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. payments of debt issuance costs for fiscal 2024 was $2.25M, a 22.18% decline from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. payments of debt issuance costs for fiscal 2023 was $2.89M.
- IRONWOOD PHARMACEUTICALS, INC. payments of debt issuance costs for fiscal 2017 was $235.00K, a 4.47% decline from fiscal 2016.
- IRONWOOD PHARMACEUTICALS, INC. payments of debt issuance costs for fiscal 2016 was $246.00K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2024-12-31 | $90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.25M 10-K · filed 2026-02-26 | ||
| 2024-09-30 | $2.16M 10-Q · filed 2024-11-07 | |||
| 2023-12-31 | $591.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $591.00K derived: sum of 2 quarters · filed 2025-03-31 | $2.89M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.29M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $2.29M 10-Q · filed 2024-08-08 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $0.00 derived: sum of 2 quarters · filed 2020-02-13 | $26.00K derived: sum of 3 quarters · filed 2020-02-13 | $235.00K 10-K · filed 2020-02-13 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $26.00K derived: sum of 2 quarters · filed 2018-11-06 | $235.00K 10-Q · filed 2018-11-06 | $281.00K derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $235.00K 10-Q · filed 2018-08-06 | $281.00K derived: sum of 3 quarters · filed 2019-02-25 | |
| 2017-03-31 | $209.00K 10-Q · filed 2018-05-04 | $255.00K derived: sum of 2 quarters · filed 2019-02-25 | ||
| 2016-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $246.00K 10-K · filed 2019-02-25 | ||
| 2016-09-30 | $200.00K 10-Q · filed 2017-11-02 | |||
| 2015-09-30 | $752.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $11.68M 10-Q · filed 2015-11-05 | ||
| 2015-06-30 | $10.93M 10-Q · filed 2016-08-08 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $0.00 derived: sum of 2 quarters · filed 2016-02-19 | $0.00 derived: sum of 3 quarters · filed 2016-02-19 | $7.72M 10-K · filed 2016-02-19 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $0.00 derived: sum of 2 quarters · filed 2014-11-05 | $7.72M 10-Q · filed 2014-11-05 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $7.72M 10-Q · filed 2014-08-05 | ||
| 2013-03-31 | $7.72M 10-Q · filed 2014-04-29 | |||
| 2011-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $206.00K 10-Q · filed 2011-11-09 | ||
| 2011-06-30 | $146.00K 10-Q · filed 2011-08-12 | |||
| 2010-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $1.89M 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | $657.00K 10-Q · filed 2011-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |